Innovative liposomal drug delivery platform by Lipella Pharmaceuticals has received U.S. patent allowance

2 min read | October 15, 2024 02:29 AM PDT | By Team Kalkine Media

Google News:

Innovative liposomal drug delivery platform by Lipella Pharmaceuticals has received U.S. patent allowance — Image source: Shutterstock

Recent News

Is Pitney Bowes Still Hiding Value After Its Rally?

What’s Driving Unity Bancorp Climb To New Highs?

Why United Parcel Service Is Back on The Market Radar?

Why Is Halliburton Facing Fresh Market Pressure?

Make Kalkine Media
My Trusted Source

Highlights:

Lipella Pharmaceuticals has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for its proprietary liposomal drug delivery platform.

The patent, titled 'Delivery of Agents Using Metastable Liposomes,' encompasses significant innovations for targeted therapeutic delivery.

This breakthrough technology enhances safety and efficacy across various therapeutic areas, including oncology and immunotherapy.

Lipella Pharmaceuticals (NASDAQ:LIPO) has announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for its proprietary liposomal drug delivery platform. The patent application, entitled "Delivery of Agents Using Metastable Liposomes," addresses key advancements in Lipella's technology, which is designed to facilitate the delivery of therapeutic agents using liposome-based vehicles.

This innovative platform allows for precise and targeted delivery of therapeutic agents, significantly enhancing safety and efficacy across multiple therapeutic areas. Notably, the technology has applications in oncology, cancer survivorship, and immunotherapy. The granted patent offers broad intellectual property protection for Lipella's drug delivery platform, which is specifically optimized for delivering agents to epithelial tissues. This protection is crucial as it extends market exclusivity for two of Lipella's lead clinical assets currently undergoing Phase 2 trials.

Dr. Michael Chancellor, Chief Medical Officer of Lipella, emphasized the importance of this milestone in the development of therapies for conditions such as hemorrhagic cystitis and oral lichen planus. The company’s liposomal drug delivery system provides a safer and more effective method for administering therapeutics like tacrolimus, targeting disease sites directly while minimizing systemic side effects.

This patent allowance represents a significant advancement for Lipella Pharmaceuticals, reinforcing its commitment to developing innovative therapeutic solutions that improve patient outcomes. As the company continues to progress through its clinical trials, the patented technology is expected to play a pivotal role in delivering enhanced treatment options to patients.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.